BioSpace News Archive

Pharm Country

Qrons files U.S. National Phase of its Patent Application in Furtherance of its QS200 Product Candidate for Therapeutic Polypseudorotaxane Hydrogels

Qrons Inc. (OTCQB:QRON) today announced that it has filed an International Patent Application at the International Bureau, for inventions of Therapeutic Polypseudorotaxane Hydrogels.

March 22, 2023
·
3 min read
Biotech Bay

Regencor Expands Scientific Advisory Board

Regencor Inc. a life sciences company that is focused on the development of therapies for treatment of cardiovascular disease, announced it has appointed Philip Janiak, Ph.D. and Ken Mahaffey, M.D. to its Scientific Advisory Board.

March 22, 2023
·
3 min read
Relief Therapeutics Announces Survey Results Identifying Preferred Urea Cycle Disorder Treatment Attributes Presented by Collaboration Partner at SIMD 2023

RELIEF THERAPEUTICS Holding SA announces survey results identifying preferred urea cycle disorder treatment attributes from its collaboration partner ACER Therapeutics, Inc.

March 22, 2023
·
8 min read
Business

TaiGen Enters Exclusive License Agreement with Joincare for TG-1000 in China

TaiGen Biotechnology Company, Limited announces that they have signed an exclusive licensing agreement with Joincare Pharmaceutical Group Industry Co., Ltd., a top 10 China pharmaceutical company, to develop and commercialize TG-1000 in China.

March 22, 2023
·
3 min read
Biotech Bay

Quince Therapeutics Confirms Receipt of Unsolicited Acquisition Offer from Echo Lake Capital

Quince Therapeutics, Inc., a biotechnology company focused on acquiring, developing, and commercializing innovative therapeutics that transform patients’ lives, confirmed that it received an unsolicited offer to acquire the company from Echo Lake Capital.

March 22, 2023
·
2 min read
Pharm Country

EvolveImmune Therapeutics Presents New Preclinical Data Demonstrating Improved Anti-Tumor Potential of Novel Costimulatory T Cell Engager Platform at Festival of Biologics Immunotherapy World Congress

EvolveImmune Therapeutics today announced that new preclinical data on EVOLVE™, the company’s novel costimulatory T cell engager platform, were featured in an oral presentation at the Festival of Biologics Immunotherapy World Congress.

March 22, 2023
·
6 min read
FDA

Avadel Pharmaceuticals Announces FDA Authorization to Import Tentatively-Approved LUMRYZ™ Ahead of Anticipated Final Approval Decision

Avadel Pharmaceuticals plc today announced that the U.S. Food and Drug Administration (“FDA”) has approved its Pre-Launch Activities Importation Requests (PLAIR) for LUMRYZ.

March 22, 2023
·
5 min read
Drug Development

89bio’s Phase 2b ENLIVEN Trial of Pegozafermin in Nonalcoholic Steatohepatitis (NASH) Achieved High Statistical Significance on Both Primary Histology Endpoints with Weekly (QW) and Every-Two-Week (Q2W) Dosing at 24 Weeks

89bio, Inc. today announced positive topline data from the Phase 2b ENLIVEN trial evaluating treatment with pegozafermin in patients with nonalcoholic steatohepatitis (NASH).

March 22, 2023
·
12 min read
Business

WILLOW & SUANFARMA ANNOUNCE COMPLETED DEVELOPMENT AND MANUFACTURING PROCESS FOR CBG AND COMMITMENT TO THE PRODUCTION OF NEW MOLECULES IN A NATURAL WAY

WILLOW BIOSCIENCES, (TSX: WLLW) (OTCQB: CANSF) and SUANFARMA today jointly announced that they have, together with SUANFARMA’s CIPAN manufacturing site, completed the development and manufacturing process in pilot scale for the WILLOW-owned ingredient, Cannabigerol (CBG).

March 22, 2023
·
5 min read
Medexus Announces New License Deal for Topical Terbinafine

Medexus Pharmaceuticals (TSX: MDP; OTCQX: MEDXF) is pleased to announce that the company has secured Canadian rights to commercialize terbinafine hydrochloride nail lacquer supplied by Polichem, an Almirall group company focused on medical dermatological treatments for skin health.

March 22, 2023
·
4 min read